Skip to main content

Table 5 Indication of denosumab for GCTBa in 24 institutions

From: Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study

Indications of denosumab No. of institutions (%)
Unresectable 21 (88%)
Difficult to joint preservation 17 (71%)
Expanding to soft tissue 11 (46%)
Adjusting the time of operation 7 (29%)
Perioperative use with curettage 6 (25%)
No experience of denosumab use 3 (13%)
  1. aGCTB, giant cell tumor of bone; some of the replies by responded institutions are overlapped